FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Haemonetics Corporation Stock AnalysisComprehensive stock analysis for Haemonetics Corporation (HAE) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisHAE
HAE
Haemonetics Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
HAE
Home🔹Stocks🔹Haemonetics Corporation

Haemonetics Corporation

🇺🇸HAE•NYSE

Haemonetics Corporation

🇺🇸HAE•NYSE
Market cap
$4.67B
Sentiment

Your view on HAE

Mkt Cap
$4.67B
Sentiment
Your view
HAE
Haemonetics Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
HAE
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Haemonetics Corporation

Industry
Medical - Devices
Sector
Healthcare
CEO
Christopher A. Simon
Headquarters
125 Summer Street, Boston, MA, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Christopher A. Simon
Headquarters
125 Summer Street, Boston, MA, US
Description

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital.

The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system.

In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries.

It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Haemonetics Corporation, and the rating behind it. HAE last traded at $102.69, 49.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Haemonetics Corporation. Starting points for Haemonetics Corporation: P/E 49.9, EPS $2.12, beta 0.54 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Haemonetics Corporation. Haemonetics Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Haemonetics Corporation. Trailing twelve-month EPS for Haemonetics Corporation stands at $2.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Haemonetics Corporation. Haemonetics Corporation has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Haemonetics Corporation valued side by side against its closest peers. Haemonetics Corporation is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Haemonetics Corporation, and how their positions are changing. At a $4.67B market value, institutional positions materially move Haemonetics Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Haemonetics Corporation executives and directors. Shares of Haemonetics Corporation have traded between $47.32 and $89.69 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Haemonetics Corporation. Haemonetics Corporation is a $4.67B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Haemonetics Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Haemonetics Corporation. Coverage tracks Haemonetics Corporation within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BEAM — Beam Therapeutics Inc.
  • BHC — Bausch Health Companies Inc.
  • CON — Concentra Group Holdings Parent, Inc.
  • ITGR — Integer Holdings Corporation
  • LMAT — LeMaitre Vascular, Inc.
  • PINC — Premier, Inc.
  • QDEL — QuidelOrtho Corporation

More Medical - Devices companies

  • CRRVF — CVR Medical Corp.
  • CSDX — CS Diagnostics Corp.
  • CSSPF — NIOX Group Plc
  • CSX.AX — CleanSpace Holdings Limited
  • CTKB — Cytek Biosciences, Inc.
  • CTSO — Cytosorbents Corporation
  • CV — CapsoVision, Inc.
  • CVRX — CVRx, Inc.
  • CYBQF — CYBERDYNE Inc.
  • CYBQY — CYBERDYNE Inc.
  • CYC.AX — Cyclopharm Limited
  • CYDX — CYduct Diagnostics, Inc.

ETFs holding Haemonetics Corporation

  • NBSM — Neuberger Berman Small-Mid Cap ETF (2.11%)
  • XHE — State Street SPDR S&P Health Care Equipment ETF (2.00%)
  • JSML — Janus Henderson Small Cap Growth Alpha ETF (1.33%)
  • TMAT — Main Thematic Innovation ETF (1.31%)
  • JSMD — Janus Henderson Small/Mid Cap Growth Alpha ETF (1.10%)
  • ROSC — Hartford Multifactor Small Cap ETF (0.97%)
  • ETHO — Amplify Etho Climate Leadership U.S. ETF (0.54%)
  • PSC — Principal U.S. Small-Cap Multi-Factor ETF (0.51%)

News

Latest Market News